The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MNPR | +222.26% | +228.39% | +26.83% | -40% |
| S&P | +12.66% | +85.37% | +13.13% | +114% |
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
No news articles found for Monopar Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $503.90M | 2023.7% |
| Market Cap / Employee | $31.49M | 0.0% |
| Employees | 16 | 60.0% |
| Net Income | -$3.44M | -163.6% |
| EBITDA | -$4.09M | -159.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $127.68M | 2020.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.07M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -25.88% | 62.4% |
| Return On Invested Capital | -74.21% | 1.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.09M | -94.7% |
| Operating Free Cash Flow | -$2.09M | -94.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 15.68 | 4.04 | 4.08 | 9.59 | 146.06% |
| Price to Tangible Book Value | 15.68 | 4.04 | 4.08 | 9.59 | 146.06% |
| Enterprise Value to EBITDA | -4.30 | -62.03 | -60.99 | -107.06 | 852.18% |
| Return on Equity | -51.4% | -54.3% | -59.4% | -26.5% | -76.31% |
| Total Debt | $0.00M | $0.00M | $0.11M | $0.07M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
